[1] Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function [J]. Genom Proteom Bioinf, 2015,13(1):17-24.
[2] Raposo G, Nijman H W, Stoorvogel W, et al.B lymphocytes secrete antigen-presenting vesicles[J]. J Exp Med, 1996, 183(3):1161-1172.
[3] Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells [J]. Nat Cell Biol, 2007, 9(6):654-659.
[4] Yang B, Chen Y, Shi J. Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms[J]. Adv Mater, 2019, 31(2): e1802896.
[5] He C, Zheng S, Luo Y, et al. Exosome theranostics: biology and translational medicine [J]. Theranostics, 2018, 8(1): 237-255.
[6] Doyle L M, Wang M Z. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis [J]. Cells, 2019, 8(7):727.
[7] Li Z, Zhao P, Zhang Y, et al. Exosome-based?Ldlr?gene therapy for familial hypercholesterolemia in a mouse mode l[J]. Theranostics, 2021, 11(6):2953-2965.
[8] Li Z, Zhou X, Wei M, et al. In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9 [J]. Nano Lett, 2019, 19(1):19-28.
[9] Yu X, Odenthal M, Fries J W. Exosomes as miRNA carriers: formation-function-future [J]. Int J Mol Sci, 2016, 17(12): 2028.
[10] Li P, Kaslan M, Lee S H, et al.Progress in exosome isolation techniques[J]. Theranostics, 2017, 7(3):789-804.
[11] Yu L L, Zhu J, Liu J X, et al.A Comparison of traditional and novel methods for the separation of exosomes from human samples[J]. Biomed Res Int, 2018, 2018: 3634563.
[12] Wei H, Qian X, Xie F, et al. Isolation of exosomes from serum of patients with lung cancer: a comparison of the ultra-high speed centrifugation and precipitation methods [J]. Ann Transl Med, 2021, 9(10):882.
[13] Zhang Y, Bi J, Huang J, et al. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications [J]. Int J Nanomedicine, 2020, 15: 6917-6934.
[14] Lu Y, Liu D, Feng Q, et al. Diabetic nephropathy: perspective on extracellular vesicles [J]. Front Immunol, 2020, 11: 943.
[15] Wang Y Y, Tang L Q, Wei W. Berberine attenuates podocytes injury caused by exosomes derived from high glucose-induced mesangial cells through TGFβ₁-PI3K/AKT pathway [J]. Eur J Pharmacol, 2018, 824: 185-192.
[16] Zhu Q J, Zhu M, Xu X X, et al. Exosomes from high glucose-treated macrophages activate glomerular mesangial cells via TGF-β₁/Smad3 pathway in vivo and in vitro[J]. FASEB J, 2019, 33(8): 9279-9290.
[17] Wen J, Ma Z, Livingston M J, et al. Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease[J]. Am J Physiol Renal Physiol, 2020, 319(4):F664-F673.
[18] He X, Kuang G, Wu Y, et al. Emerging roles of exosomal miRNAs in diabetes mellitus[J]. Clin Transl Med, 2021, 11(6): e468.
[19] Cheng Q, Pan J, Zhou Z L, et al. Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy[J]. Acta Pharmacol Sin, 2021, 42(6): 954-963.
[20] Chen J, Zhang Q, Liu D, et al. Exosomes: advances, development and potential therapeutic strategies in diabetic nephropathy[J]. Metabolism, 2021, 122:154834.
[21] Delic D, Eisele C, Schmid R, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients[J]. PLoS One, 2016, 11(3): e0150154.
[22] Khan N U, Lin J, Liu X, et al. Insights into predicting diabetic nephropathy using urinary biomarkers[J]. Biochim Biophys Acta Proteins Proteom, 2020, 1868(10):140475.
[23] Kim H, Bae Y U, Jeon J S, et al. The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy[J]. J Transl Med, 2019, 17(1):236.
[24] Lee W C, Li L C, Ng H Y, et al. Urinary exosomal MicroRNA signatures in nephrotic, biopsy-proven diabetic nephropathy[J]. J Clin Med, 2020, 9(4):1220.
[25] Jin J, Shi Y, Gong J, et al. Huang H. Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte[J]. Stem Cell Res Ther, 2019, 10(1): 95.
[26] Jin J, Wang Y, Zhao L, et al. Exosomal miRNA-215-5p derived from adipose-derived stem cells attenuates epithelial-mesenchymal transition of podocytes by inhibiting ZEB2[J]. Biomed Res Int, 2020, 2020: 2685305.
[27] Gao C, Wang B, Chen Q, et al. Serum exosomes from diabetic kidney disease patients promote pyroptosis and oxidative stress through the miR-4449/HIC1 pathway[J]. Nutr Diabetes, 2021, 11(1): 33.
[28] Mao R, Shen J, Hu X. BMSCs-derived exosomal microRNA-let-7a plays a protective role in diabetic nephropathy via inhibition of USP22 expression [J]. Life Sci, 2021, 268: 118937.
[29] Duan Y R, Chen B P, Chen F, et al. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte[J]. J Cell Mol Med, 2021, 25(23):10798-10813.
[30] Lv L L, Feng Y, Wu M, et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury [J]. Cell Death Differ, 2020, 27(1): 210-226.
[31] Huang H, Liu H, Tang J, et al. M2 macrophage-derived exosomal miR-25-3p improves high glucose-induced podocytes injury through activation autophagy via inhibiting DUSP1 expression[J]. IUBMB Life, 2020, 72(12): 2651-2662.